“We thought if we focused on the R&D spending of some pharmaceutical companies that have only one FDA-approved cancer drug in the market, we might be able to better estimate the cost of developing a cancer drug. We were surprised to see our analysis show this cost to be about $648 mill...
The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the ...
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion...
Future studies will also delve deeper into cell-based therapy, an immunotherapy strategy that positions the body’s immune cells to recognize antigen signals and attack dangeours tumors. This treatment method, also known as chimeric antigen receptor therapy, or CAR therapy, has demonstrated efficacy ...
Recent approvals from the Food and Drug Administration (FDA) have created controlled chaos with pharmaceutical development companies being purchased at sky-high multiples and drug treatment costs reaching stratospheric heights. Kite Pharma, the developer of an FDA-approved treatment which genetically alters...
pharmaceutical companies may be preventing us from effective advocacy. We also need to generate specific treatment guidelines that take cost into account. Current guidelines often present a list of acceptable treatment options for a given condition, without clear recommendation that guides patients and ...
Academics, patient advocates and many pharmaceutical companies aim to follow a similar path in multiple myeloma. “Evidence is accumulating,” says Ola Landgren, who is professor of medicine and chief of the myeloma service at Memorial Sloan Kettering Cancer Center. For example, multiple myeloma pati...
or cancer treatment Pharmaceutical composition for cancer treatmentPharmaceutical composition for cancer treatmentdoi:WO2009101225 A1WO
Pharma Mar is a pharmaceutical company focused on research and development of new cancer treatments. The company has developed and currently markets Yondelis in Europe, as well as Zepzelca (lurbinectedin) in the United States and Aplidin (plitidepsin) in Australia, with different partners. Hea...
ATOM works with pharmaceutical companies to map their medicine portfolios and determine how access could be expanded in target ATOM countries. Going forward, it plans to include diagnostic companies, and to reduce transaction and rollout costs via mechanisms such as a single medicine registration proces...